D-methadone clinical trials
Also written REL-1017 and esmethadone.
How each study uses D-methadone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2018 | 1 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 2
Relmada Therapeutics, Inc. (6) · Levomecor Inc. (2) · Memorial Sloan Kettering Cancer Center (1) · Mauro Manconi (1) · MGGM LLC (1)
Related medicines
As reviewed, each with the page that says it.
- An enantiomer of Methadone source
- One of Analgesics, Non-Narcotic source
Studies
Open first, then newest update. How each study uses D-methadone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)TerminatedPhase 3Levomecor Inc.NCT04855747Written as REL-1017
- Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDDTerminatedPhase 3Levomecor Inc.NCT06011577Written as REL-1017
- A Proof of Concept, Phase 2, Double-blind, Randomized Trial With d-Methadone Product Versus PlaceboSuspendedPhase 2Mauro ManconiNCT04145674Written as D-methadone
- Safety of REL-1017 for Major Depressive DisorderCompletedPhase 3Relmada Therapeutics, Inc.NCT04855760Written as REL-1017
- A Study to Evaluate the Efficacy and Safety of REL-1017 As Adjunctive Treatment of Major Depressive Disorder (MDD)WithdrawnPhase 3MGGM LLCNCT06735079Written as REL1017 (esmethadone HCI) (active drug)
- A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)CompletedPhase 3Relmada Therapeutics, Inc.NCT04688164Written as REL-1017
- A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)CompletedPhase 3Relmada Therapeutics, Inc.NCT05081167Written as REL-1017
- Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDDCompletedPhase 2Relmada Therapeutics, Inc.NCT03051256Written as REL-1017
- Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of REL-1017 (d-Methadone)CompletedPhase 1Relmada Therapeutics, Inc.NCT03637361Written as REL-1017
- Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REL-1017 (d-Methadone)CompletedPhase 1Relmada Therapeutics, Inc.NCT03638869Written as REL-1017
- Study of D-Methadone in Patients With Chronic PainCompletedPhase 1/2Memorial Sloan Kettering Cancer CenterNCT00588640Written as d-Methadone
Codes
What other systems call D-methadone · ClinicalTrials.gg INT000918
- MeSH (NLM) C000626862D-methadoneOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000626862 | D-methadone | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.